SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically advance the understanding of the risks associated with multiple cancer genes that are being analyzed through next generation sequencing technology. Specifically, the partners will collaborate on the creation of a research study called the Prospective Registry of Multiplex Testing (PROMPT).
The goals of the study are three-fold: 1) to create an online registry of individuals consenting to a prospective follow up after having been tested with a pan-cancer panel test such as Myriad's myRisk™ Hereditary Cancer; 2) to provide infrastructure for the curation of specific genetic variants detected; and 3) to facilitate additional studies to characterize the significance of the genetic mutations. Myriad will contribute thousands of genetic mutations and its scientific expertise gained from having tested over 1.3 million patients for hereditary cancer risk.
"We look forward to collaborating with leading cancer centers to help end preventable hereditary cancers. Myriad's contribution of thousands of genetic mutations to the PROMPT study will help make this goal a reality by ensuring that researchers have access to critical, potentially life-saving information," said Richard Wenstrup, M.D. chief medical officer at Myriad. "Through this innovative data sharing partnership with some of the country's best cancer genetics centers, we can more efficiently study genetic mutations, maximize the impact of our research investments and help ensure that patients will receive the best care possible."This announcement continues Myriad's long-standing commitment to research collaborations. Myriad currently is engaged in scientific collaborations with more than 50 academic research institutions to help advance medical and scientific knowledge and healthcare overall. For more information visit: www.myriad.com/responsibility/research-collaborations/ . About the Prospective Registry of Multiplex Testing (PROMPT) The PROMPT registry is a database that will include patients identified with deleterious or suspected deleterious mutations in any of the cancer susceptibility genes targeted in this research study. Individuals will be offered the opportunity to join the registry by participating in a process of informed consent. The study's Principal Investigators are Mark Robson, M.D., of the Clinical Genetics Service at MSKCC; Susan Domchek, M.D., of the Abramson Cancer Center of the University of Pennsylvania; Fergus Couch, Ph.D., of the Division of Experimental Pathology, Mayo Clinic and Kenneth Offit, M.D., MPH, chief of the Clinical Genetics Service at MSKCC.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts